MA46460A - Formes cristallines et salines de composés agonistes de ppar - Google Patents
Formes cristallines et salines de composés agonistes de pparInfo
- Publication number
- MA46460A MA46460A MA046460A MA46460A MA46460A MA 46460 A MA46460 A MA 46460A MA 046460 A MA046460 A MA 046460A MA 46460 A MA46460 A MA 46460A MA 46460 A MA46460 A MA 46460A
- Authority
- MA
- Morocco
- Prior art keywords
- crystalline
- agonist compounds
- ppar agonist
- saline forms
- saline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404474P | 2016-10-05 | 2016-10-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46460A true MA46460A (fr) | 2021-03-17 |
Family
ID=60153508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046460A MA46460A (fr) | 2016-10-05 | 2017-10-05 | Formes cristallines et salines de composés agonistes de ppar |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US10927094B2 (fr) |
| EP (1) | EP3523283B1 (fr) |
| JP (1) | JP7017563B2 (fr) |
| KR (1) | KR20190057129A (fr) |
| CN (1) | CN109843857B (fr) |
| AU (1) | AU2017340763B2 (fr) |
| BR (1) | BR112019006030A2 (fr) |
| CA (1) | CA3036587A1 (fr) |
| CO (1) | CO2019003162A2 (fr) |
| CY (1) | CY1124655T1 (fr) |
| DK (1) | DK3523283T3 (fr) |
| ES (1) | ES2887008T3 (fr) |
| HR (1) | HRP20211341T1 (fr) |
| HU (1) | HUE055678T2 (fr) |
| IL (1) | IL265730B (fr) |
| JO (1) | JOP20190039B1 (fr) |
| LT (1) | LT3523283T (fr) |
| MA (1) | MA46460A (fr) |
| MX (1) | MX2019003945A (fr) |
| MY (1) | MY202008A (fr) |
| PH (1) | PH12019500727A1 (fr) |
| PL (1) | PL3523283T3 (fr) |
| PT (1) | PT3523283T (fr) |
| RS (1) | RS62245B1 (fr) |
| RU (1) | RU2759724C2 (fr) |
| SG (1) | SG11201901995TA (fr) |
| SI (1) | SI3523283T1 (fr) |
| TW (1) | TWI769182B (fr) |
| UA (1) | UA124770C2 (fr) |
| WO (1) | WO2018067860A1 (fr) |
| ZA (1) | ZA201901744B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1888548B1 (fr) | 2005-05-26 | 2012-08-22 | Neuron Systems, Inc | Dérivé de quinoline pour le traitement de maladies rétiniennes |
| HUE058154T2 (hu) * | 2015-10-07 | 2022-07-28 | Mitobridge Inc | PPAR agonisták, vegyületek, gyógyászati készítmények és módszerek alkalmazásukra |
| CN109843857B (zh) | 2016-10-05 | 2023-01-06 | 米托布里奇公司 | Ppar激动剂化合物的结晶和盐形式 |
| MX2020003425A (es) | 2017-10-10 | 2020-07-29 | Aldeyra Therapeutics Inc | Tratamiento de trastornos inflamatorios. |
| JP2021533154A (ja) * | 2018-08-06 | 2021-12-02 | アルデイラ セラピューティクス， インコーポレイテッド | 多形化合物およびその使用 |
| US20220031666A1 (en) * | 2018-10-23 | 2022-02-03 | Japan Science And Technology Agency | PPARo ACTIVATOR |
| CA3221429A1 (fr) | 2021-06-02 | 2022-12-08 | Astellas Pharma Inc. | Procedes d'utilisation de composes agonistes ppar et compositions pharmaceutiques associees |
| WO2023147309A1 (fr) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Utilisation d'agonistes ppar-delta dans le traitement d'une maladie |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004063166A1 (fr) | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Modulateurs de ppar heterocycliques |
| EP1671633A1 (fr) | 2004-12-17 | 2006-06-21 | Sanofi-Aventis Deutschland GmbH | Utilisation de PPAR agonistes pour traiter l'insuffisance cardiaque congestive |
| JP2008528700A (ja) | 2005-02-03 | 2008-07-31 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｐｐａｒモジュレーターとしての化合物および組成物 |
| CN101296892A (zh) * | 2005-09-07 | 2008-10-29 | 普莱希科公司 | Ppar活性化合物 |
| DE102006023336A1 (de) * | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole II |
| FR2940289B1 (fr) * | 2008-12-23 | 2014-09-12 | Biopharmed | Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas |
| CN102727489A (zh) * | 2012-07-18 | 2012-10-17 | 西南大学 | 5-芳(杂环)亚甲基噻唑烷-2，4-二酮在制备ppar激动剂中的应用 |
| WO2016057658A1 (fr) | 2014-10-08 | 2016-04-14 | Mitobridge, Inc. | Agonistes de ppar, composés, compositions pharmaceutiques et méthodes d'utilisation de ceux-ci |
| HUE058154T2 (hu) * | 2015-10-07 | 2022-07-28 | Mitobridge Inc | PPAR agonisták, vegyületek, gyógyászati készítmények és módszerek alkalmazásukra |
| RU2746602C2 (ru) * | 2016-04-13 | 2021-04-16 | Митобридж, Инк. | Агонисты ppar, соединения, фармацевтические композиции и способы их применения |
| CA3036723A1 (fr) * | 2016-10-05 | 2018-04-12 | Mitobridge, Inc. | Methode de traitement de lesions renales aigues |
| CN109843857B (zh) | 2016-10-05 | 2023-01-06 | 米托布里奇公司 | Ppar激动剂化合物的结晶和盐形式 |
-
2017
- 2017-10-05 CN CN201780062034.5A patent/CN109843857B/zh active Active
- 2017-10-05 JP JP2019518286A patent/JP7017563B2/ja active Active
- 2017-10-05 RS RS20211042A patent/RS62245B1/sr unknown
- 2017-10-05 WO PCT/US2017/055403 patent/WO2018067860A1/fr active Application Filing
- 2017-10-05 DK DK17787774.3T patent/DK3523283T3/da active
- 2017-10-05 JO JOP/2019/0039A patent/JOP20190039B1/ar active
- 2017-10-05 UA UAA201903678A patent/UA124770C2/uk unknown
- 2017-10-05 US US16/334,746 patent/US10927094B2/en active Active
- 2017-10-05 CA CA3036587A patent/CA3036587A1/fr active Pending
- 2017-10-05 RU RU2019110736A patent/RU2759724C2/ru active
- 2017-10-05 PT PT177877743T patent/PT3523283T/pt unknown
- 2017-10-05 LT LTEPPCT/US2017/055403T patent/LT3523283T/lt unknown
- 2017-10-05 KR KR1020197012668A patent/KR20190057129A/ko not_active Application Discontinuation
- 2017-10-05 BR BR112019006030A patent/BR112019006030A2/pt active Search and Examination
- 2017-10-05 HU HUE17787774A patent/HUE055678T2/hu unknown
- 2017-10-05 ES ES17787774T patent/ES2887008T3/es active Active
- 2017-10-05 MY MYPI2019001560A patent/MY202008A/en unknown
- 2017-10-05 MA MA046460A patent/MA46460A/fr unknown
- 2017-10-05 SG SG11201901995TA patent/SG11201901995TA/en unknown
- 2017-10-05 PL PL17787774T patent/PL3523283T3/pl unknown
- 2017-10-05 MX MX2019003945A patent/MX2019003945A/es unknown
- 2017-10-05 AU AU2017340763A patent/AU2017340763B2/en active Active
- 2017-10-05 TW TW106134298A patent/TWI769182B/zh active
- 2017-10-05 SI SI201730879T patent/SI3523283T1/sl unknown
- 2017-10-05 EP EP17787774.3A patent/EP3523283B1/fr active Active
- 2017-10-05 IL IL265730A patent/IL265730B/en unknown
-
2019
- 2019-03-20 ZA ZA2019/01744A patent/ZA201901744B/en unknown
- 2019-03-29 CO CONC2019/0003162A patent/CO2019003162A2/es unknown
- 2019-04-03 PH PH12019500727A patent/PH12019500727A1/en unknown
-
2021
- 2021-02-19 US US17/179,604 patent/US11530192B2/en active Active
- 2021-08-20 HR HRP20211341TT patent/HRP20211341T1/hr unknown
- 2021-08-31 CY CY20211100775T patent/CY1124655T1/el unknown
-
2022
- 2022-12-16 US US18/082,847 patent/US11912681B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46460A (fr) | Formes cristallines et salines de composés agonistes de ppar | |
| DK3866587T3 (da) | Overvågning af husdyr | |
| MA50567A (fr) | Nouveaux composés de sulfonamide carboxamide | |
| MA49901A (fr) | Nouveaux composés de sulfonamide carboxamide | |
| MA49904A (fr) | Nouveaux composés de sulfonamide carboxamide | |
| MA56075A (fr) | Nouveaux composés de sulfonamide carboxamide | |
| DK3883936T3 (da) | Nye heterocykliske forbindelser | |
| MA49908A (fr) | Composés inhibant la protéine mcl-1 | |
| MA52948A (fr) | Composés | |
| MA47596A (fr) | Formes cristallines du dérivé 4-pyrimidinesulfamide aprocitentan | |
| MA51669A (fr) | Composés | |
| DK3104847T3 (da) | Hidtil ukendt anvendelse af sigma-1-receptoragonistforbindelser | |
| DK3328395T3 (da) | Ny brug af dextransulfat | |
| FR3056393B1 (fr) | Orthese d'extension de machoires | |
| DK3430004T3 (da) | Faststofformer af nilotinibsalte | |
| DK3695585T4 (da) | Overvågning af varmeforbrug | |
| DK3248964T3 (da) | Thiazol-modulatorer af A3-adenosinreceptorer | |
| MA45686A (fr) | Formes salines de 4-cyano-n-(2-(4,4-diméthylcyclohex-1-en-1-yl)-6-(2,2,6,6-tétraméthyltétrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide | |
| DK3633331T3 (da) | Overvågning af maskinvibration | |
| MA46464A (fr) | Polymorphes de l'agoniste de récepteur muscarinique | |
| ES2743719R1 (es) | Nuevas fases solidas de rifaximina | |
| ES2782400R1 (es) | Creacion de lentes regrabables | |
| MA49740A (fr) | Nouveaux composés de sulfonamide carboxamide | |
| UA39602S (uk) | Комплект етикеток | |
| UA38661S (uk) | Комплект етикеток |